Achillion Pharmaceuticals, Inc. (ACHN) saw its loss widen to $20.15 million, or $0.15 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $18.05 million, or $0.13 a share.
The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $21.14 million, compared with an operating loss of $18.72 million in the previous year period.
"During the first quarter of 2017, we advanced our first, orally administered factor D inhibitor, ACH-4471, into Phase 2 development for PNH. As we continue to enroll patients into this study, the first two PNH patients have now completed 28 days of dosing. After assessment of safety and efficacy by the investigators both patients continue to receive up to two additional months of therapy. Our plan is to submit interim results from this study for presentation at a major medical conference this quarter," commented Milind Deshpande, Ph.D., President and chief executive officer of Achillion.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
